• PN: B113385

COMPONENTS

45x Ab-conjugated beads (S5P8- human sPD-1 Ab-bead). PN: B113385A. One vial containing 100 µL of anti-human sPD-1 conjugated to AimPlex Bead S5P8.

25x Biotin-detection Ab (human sPD-1 Biotin-dAb). PN: B113385B. One vial containing 100 µL of biotinylated anti-human sPD-1.

Lyophilized Standard Mix-Human Group 7, Panel B, 7-Plex. PN: HG72006. One vial containing lyophilized recombinant NAP-2, PARC, sPD-1, PF4, SDF-1, TARC, and TECK.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human PD-1/sCD279 . Can be multiplexed with other analytes in Human Group 7.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 20 pg/mL

Quantitation range:

LLOQ: < 50 pg/mL

ULOQ: > 10,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 7: Negligible

Sample volume: 15 µL/test

Description:

Programmed cell death protein 1, also known as PD-1 and CD279, is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 binds two ligands, PD-L1 and PD-L2. PD-1, functioning as an immune checkpoint, plays an important role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells). PD-1 inhibitors, a new class of drugs that block PD-1, activate the immune system to attack tumors and are therefore used with varying success to treat some types of cancer. Diseases associated with PDCD1 include systemic lupus erythematosus 2 and multiple sclerosis.

References:

1.      Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T (Oct 1994). "Structure and chromosomal localization of the human PD-1 gene (PDCD1)". Genomics 23 (3): 704–6. doi:10.1006/geno.1994.1562. PMID 7851902.

2.      Francisco LM, Sage PT, Sharpe AH (Jul 2010). "The PD-1 pathway in tolerance and autoimmunity". Immunological Reviews 236: 219–42. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.

3.      Fife BT, Pauken KE (Jan 2011). "The role of the PD-1 pathway in autoimmunity and peripheral tolerance". Annals of the New York Academy of Sciences 1217: 45–59. doi:10.1111/j.1749-6632.2010.05919.x. PMID 21276005.

4.      Loftus, Peter (16 Nov 2014). "New Bristol-Myers Drug Helped Skin-Cancer Patients in Trial Live Longer". Retrieved 24 Nov 2014.